An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Acutis Diagnostics Leverages SOPHiA GENETICS Technology to Create New Next Generation Sequencing Test
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) has partnered with Acutis Diagnostics to develop a new genomic assay using SOPHiA DDM™, aimed at enhancing patient enrollment in clinical oncology trials. This next-generation sequencing (NGS) test will leverage Acutis Diagnostics’ laboratory technologies and is designed to provide valuable insights for clinical researchers. By improving genomic screening capabilities, the assay aims to facilitate better clinical outcomes for cancer patients, many of whom have a hereditary cancer background. The collaboration underscores SOPHiA GENETICS' commitment to advancing data-driven medicine in oncology.
Positive
Partnership with Acutis Diagnostics to enhance genomic assay development.
Utilization of SOPHiA DDM™ to support clinical trial efficiency.
Focus on hereditary cancer solutions, potentially benefiting a significant patient demographic.
Negative
None.
The New Assay Will Screen Patients for Clinical Trials and Help Increase Data Analysis for Clinical Researchers
BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Acutis Diagnostics, a specialized medical laboratory, will use SOPHiA DDM™ to develop a new genomic assay. This new next-generation sequencing (NGS) test will build on Acutis Diagnostics’ track record of approved lab-developed tests that support clinical trials, cancer research and treatment.
To create the new assay, Acutis Diagnostics will pair SOPHiA DDM™ for Hereditary Cancers Solution with their laboratory analysis technologies. The test is in support of genomic screening for patient enrollment in oncology clinical trials and for retrospective analyses to help explain clinical outcomes and drug target discovery.
“The use of SOPHiA DDM™ will help us quickly launch this new assay to aid clinical researchers in speeding up the process for launching select clinical oncology trials and ensuring the most appropriate patients are enrolled,” said Dr. Abdel Halim, Chief Scientific Officer and Executive Vice President, Acutis Diagnostics. “Additionally, the test is to provide researchers with a robust set of data and insights to support clinical decision-making and future research.”
“Our work at SOPHiA GENETICS is focused on creating technology and solutions that make it easier for everyone to practice and benefit from data-driven medicine,” said Ken Freedman, Chief Revenue Officer, SOPHiA GENETICS. “The new assay from Acutis Diagnostics will be designed to enable clinical researchers to work faster, and with a sound set of insights around their data, ultimately benefitting their current and future patients, as well as the industry as a whole.”
An estimated 20% of cancer patients have a family history of cancer.1 Next-generation sequencing (NGS) is the technology of choice in detecting biomarkers for hereditary cancers and identifying mutations that help to inform treatment options. The SOPHiA GENETICS hereditary cancer solutions are NGS-based applications that use artificial intelligence and machine learning with patented technologies to analyze raw NGS data and provide simplified insights. This technology enables clinical researchers to accurately characterize the complex mutational landscape associated with major hereditary cancer disorders.
Through the use of SOPHiA GENETICS’ technology, the new assay from Acutis Diagnostics is expected to further clinical research and treatments for those who encounter hereditary cancers.
About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native software company in the healthcare space dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad global network of hospitals, academic centers, laboratories and biopharma institutions. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. Where others see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
__________________________
1Al Harthi, F. S., et al. (2020) ‘Familial/inherited cancer syndrome: a focus on the highly consanguineous Arab population’, npj Genomic Medicine, 5, 3
What is the purpose of the new assay developed by SOPHiA and Acutis Diagnostics?
The new assay aims to enhance genomic screening for patient enrollment in oncology clinical trials and provide insights for clinical researchers.
How does SOPHiA DDM™ support cancer research?
SOPHiA DDM™ enhances genomic analysis and data insights, aiding researchers in clinical decision-making and future research initiatives.
What is the significance of hereditary cancers in the context of this PR?
An estimated 20% of cancer patients have a family history of cancer, highlighting the importance of hereditary cancer solutions in research and treatment.
When was the partnership between SOPHiA GENETICS and Acutis Diagnostics announced?
